Longeveron (LGVN)
Develops donor-derived cell therapy for pediatric cardiac and aging-related diseases.
$2.69
After hours−0.03 (−1.08%)
At close$2.72(+11.02%)
Something off on this page? Send us feedback.
Next report
Nov 3, 26
in 42 days
EPS estimate
−$1.95
Revenue estimate
$563.5K
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.43−$0.34−$0.33−$0.39−$2.30−$0.19−$1.90Pending
Estimate−$3.60−$3.40−$0.35−$2.60−$4.20−$1.80−$1.75−$1.95
Surprise+87.9%+90.0%+5.7%+85.0%+45.2%+89.4%−8.6%—
RevenueReportedEstimate
Feb '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$603.0K$381.0K$316.0K$137.0K$365.0K$398.0K$287.0KPending
Estimate$634.0K$594.5K$419.0K$266.0K$110.3K$334.5K$326.0K$563.5K
Surprise−4.9%−35.9%−24.6%−48.5%+230.8%+19.0%−12.0%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | −$0.11 | — | — |
| Sep 2027 | −$1.00 | — | — |
| Jun 2027 | −$1.00 | — | — |
| Mar 2027 | −$0.12 | — | — |
| Dec 2026 | −$1.75 | — | — |
| Nov 2026 | −$1.95 | — | — |
| Aug 2026 | −$1.75 | −$1.90 | −8.6% |
| May 2026 | −$1.80 | −$0.19 | +89.4% |
| Mar 2026 | −$4.20 | −$2.30 | +45.2% |
| Nov 2025 | −$2.60 | −$0.39 | +85.0% |
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Sep 2020 | |||
| Jun 2020 | |||
| Mar 2020 | |||
| Dec 2019 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | −$0.11 | — | — | $250.0K | — | — | — |
| Sep 2027 | −$1.00 | — | — | $250.0K | — | — | — |
| Jun 2027 | −$1.00 | — | — | $250.0K | — | — | — |
| Mar 2027 | −$0.12 | — | — | $251.5K | — | — | — |
| Dec 2026 | −$1.75 | — | — | $620.0K | — | — | — |
| Nov 3, 2026 | −$1.95 | — | — | $563.5K | — | — | — |
| Aug 12, 2026 | −$1.75 | −$1.90 | −8.6% | $326.0K | $287.0K | −12.0% | −6.6% |
| May 13, 2026 | −$1.80 | −$0.19 | +89.4% | $334.5K | $398.0K | +19.0% | +0.7% |
| Mar 17, 2026 | −$4.20 | −$2.30 | +45.2% | $110.3K | $365.0K | +230.8% | +8.1% |
| Nov 4, 2025 | −$2.60 | −$0.39 | +85.0% | $266.0K | $137.0K | −48.5% | −3.7% |
| Aug 13, 2025 | |||||||
| May 8, 2025 | |||||||
| Feb 28, 2025 | |||||||
| Nov 8, 2024 | |||||||
| Aug 9, 2024 | |||||||
| May 10, 2024 | |||||||
| Mar 8, 2024 | |||||||
| Nov 13, 2023 | |||||||
| Aug 11, 2023 | |||||||
| May 12, 2023 | |||||||
| Mar 10, 2023 | |||||||
| Nov 14, 2022 | |||||||
| Aug 12, 2022 | |||||||
| May 13, 2022 | |||||||
| Mar 11, 2022 | |||||||
| Nov 12, 2021 | |||||||
| Aug 13, 2021 | |||||||
| May 14, 2021 | |||||||
| Mar 30, 2021 | |||||||
| Sep 30, 2020 | |||||||
| Jun 30, 2020 | |||||||
| Mar 31, 2020 | |||||||
| Dec 31, 2019 |